Innovation & Kidney Research, The George Institute
A/Professor Meg Jardine is a Program Head of Innovation & Kidney Research at The George Institute and a practising nephrologist. Her research focus is the improvement of clinical outcomes for people with kidney disease and diabetes. Her interests include the integration of clinical care and research endeavours, and the promotion of learning health system principles to contribute to the efficient delivery. She has collaborated with ANZDATA and the AKTN to pioneer the first registry-based randomised quality improvement study in Australian dialysis care. She has experience in the design and conduct of national and international trials including practice-changing SGLT2 inhibitor and statin trials, response-adaptive trials and rapid response trials. A/Prof Jardine has benefited from the collaborative generosity of the ANZ clinical and patient community which has helped ensure trial design is relevant to clinical practice and equipoise. Her research activities has led to $24.5M of funding and over 130 peer-reviewed publications, including 80 within the last 5 years and in almost all of the major high impact factor clinical journals.
A/Prof Jardine is an Executive Committee member of the international nephrology guidelines body, KDIGO, and has contributed to Australian CARI guideline development. She contributes to policy setting and implementation through roles such as Board Member of the Kidney Health Initiative, a public-private collaboration of the American Society of Nephrology and the US FDA. Her advocacy for the kidney disease trial endeavour is pursued through roles in the AKTN, the International Society of Nephrology Advancing Clinical Trials (ISN-ACTS) core committee and the ANZSN Research Advisory Committee.”